Lysophosphatidic acid levels in cerebrospinal fluid and plasma samples in patients with major depressive disorder
Leo Gotoh,
Misa Yamada,
Kotaro Hattori,
Daimei Sasayama,
Takamasa Noda,
Sumiko Yoshida,
Hiroshi Kunugi,
Mitsuhiko Yamada
Affiliations
Leo Gotoh
Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo, 187-8553, Japan
Misa Yamada
Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo, 187-8553, Japan
Kotaro Hattori
Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, 187-8502, Japan; Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, 187-8551, Japan
Daimei Sasayama
Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, 187-8502, Japan; Department of Psychiatry, Shinshu University School of Medicine, Matsumoto, Japan
Takamasa Noda
National Center of Neurology and Psychiatry Hospital, Tokyo, 187-8551, Japan
Sumiko Yoshida
National Center of Neurology and Psychiatry Hospital, Tokyo, 187-8551, Japan; Medical Genome Center, National Center of Neurology and Psychiatry, Tokyo, 187-8551, Japan
Hiroshi Kunugi
Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, 187-8502, Japan
Mitsuhiko Yamada
Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo, 187-8553, Japan; Corresponding author.
Major depressive disorder (MDD) is the most common psychiatric disorders. However, a biochemical marker has yet to be established for clinical purposes. It is proposed that lysophosphatidic acid (LPA, 1-acyl-2-sn-glycerol-3-phosphoate) plays some important roles in emotional regulation of experimental animals. Therefore, in this study, we measured LPA levels using enzyme-linked immunosorbent assays of cerebrospinal fluid (CSF) and plasma samples from patients with MDD. The participants were 52 patients and 49 normal healthy controls for CSF study, and 47 patients and 44 controls for plasma study. We used the Japanese version of the GRID Hamilton Depression Rating Scale (17-item version) for the assessment of depressive symptoms. We found no associations between LPA levels (CSF or plasma) and either diagnosis or severity of MDD, or with psychotropic medication. In conclusion, our data suggest that LPA levels likely would not serve as a practical biomarker of MDD.
